Effect of small interfering RNA 3'-end overhangs on chemosensitivity to thymidylate synthase inhibitors.
BACKGROUND
Small interfering RNAs (siRNAs) are double-stranded RNAs that effectively inhibit expression of its complimentary target mRNA. Standard siRNAs contain two nucleotide overhangs on their 3' end. While these overhangs are usually comprised of deoxythymidines (dT), it has been shown that any nucleotide can be used on the 3' end without affecting RNAi silencing.


RESULTS
It was recently shown that extension of the 3' end to five or eight dT molecules allows siRNAs to be effectively complexed with linear polyethylenimine (PEI), leading to enhanced cellular uptake and intracellular release. Here, we provide further evidence that only extended or 'sticky' siRNAs complexed with PEI result in significant target knockdown. However, when investigating the potential effects of these extended siRNAs on growth of human colon cancer RKO cells, we observed a dose-dependent reversal of cytotoxicity of a thymidylate synthase-targeted siRNA. In contrast, siRNAs with uridine overhangs maintained their growth inhibitory effects. We further demonstrated that dT-containing siRNAs prevented the cytotoxic effects of thymidylate synthase (TS) inhibitor compounds, such as ZD1694 and 5'-fluoro-deoxyuridine, while having no deleterious effect on cisplatin toxicity. We show that this rescue effect results from the rapid degradation of the siRNA.


CONCLUSIONS
Given that TS is an important enzyme for cell growth and proliferation and that its expression is controlled by multiple pathways, the rescue of its growth inhibitory effects may have unintended consequences. As siRNAs are being developed as therapeutic molecules, it will be important to avoid such off-target effects due to dT release. Hence, siRNAs should contain only uridine residues in their 3'-end overhangs.
VACT Healthcare System, VACT Cancer Center, West Haven, CT, USA. jschmitz_sr@yahoo.com.
John C
JC
Schmitz
Edward
E
Chu
Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12938-43
19622726
Mol Cell Biol. 1995 Aug;15(8):4215-24
7623816
Small. 2009 May;5(10):1176-85
19306454
Br J Cancer. 2007 Nov 5;97(9):1242-50
17923872
EMBO J. 2000 Sep 1;19(17):4665-75
10970859
Int J Cancer. 2010 Feb 1;126(3):631-9
19621386
Mol Cancer Ther. 2006 Dec;5(12):3085-95
17172411
RNA. 2006 Jul;12(7):1197-205
16682562
Nat Methods. 2005 Apr;2(4):241
15782213
ACS Nano. 2009 Oct 27;3(10):3273-86
19739605
Biochem Biophys Res Commun. 2005 May 13;330(3):755-9
15809061
Clin Cancer Res. 2009 May 1;15(9):3189-95
19383814
Nature. 1970 Aug 15;227(5259):680-5
5432063
Annu Rev Biochem. 1995;64:721-62
7574499
Cell Cycle. 2008 Aug;7(15):2392-400
18677108
Gene Ther. 2005 Mar;12(5):461-6
15616603
PLoS One. 2009 Jun 16;4(6):e5933
19529774
J Control Release. 2005 Dec 5;109(1-3):299-316
16298009
Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16050-5
17913877
Cancer Gene Ther. 2006 Jan 1;13(1):107-14
16052228
Oligonucleotides. 2007 Summer;17(2):213-22
17638525
Cancer Res. 1992 Nov 1;52(21):5900-5
1394217
Oligonucleotides. 2009 Jun;19(2):141-50
19441891
Proc Natl Acad Sci U S A. 2010 May 11;107(19):8800-5
20421463
Science. 1987 Jan 23;235(4787):448-55
3099389
Biochim Biophys Acta. 1977 Dec 23;473(2):73-92
145246
Am J Physiol Lung Cell Mol Physiol. 2000 Nov;279(5):L872-7
11053022
Nano Lett. 2009 Jun;9(6):2402-6
19422265
Cancer Res. 1993 Dec 1;53(23):5697-706
8242626
Cancer Res. 2004 Feb 15;64(4):1431-5
14973067
Nat Mater. 2009 Jun;8(6):526-33
19404239
FASEB J. 2010 Sep;24(9):3122-34
20385622